These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34724994)

  • 1. Clinical and economic outcomes attributable to carbapenem-resistant Enterobacterales and delayed appropriate antibiotic therapy in hospitalized patients.
    Kengkla K; Wongsalap Y; Chaomuang N; Suthipinijtham P; Oberdorfer P; Saokaew S
    Infect Control Hosp Epidemiol; 2022 Oct; 43(10):1349-1359. PubMed ID: 34724994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study.
    Hoo GSR; Cai Y; Quek YC; Teo JQ; Choudhury S; Koh TH; Lim TP; Marimuthu K; Ng OT; Kwa AL
    Front Cell Infect Microbiol; 2022; 12():719421. PubMed ID: 35281438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
    Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
    Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-case-control study of risk factors for carbapenem-resistant Enterobacterales infections among hospitalized patients.
    Stuever DM; Ferketich AK; Lee J; Stevenson KB; Wittum TE
    Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e118. PubMed ID: 36483348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial Resistance or Delayed Appropriate Therapy-Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?
    Lodise TP; Berger A; Altincatal A; Wang R; Bhagnani T; Gillard P; Bonine NG
    Open Forum Infect Dis; 2019 Jun; 6(6):ofz194. PubMed ID: 31198817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients.
    Anesi JA; Lautenbach E; Thom KA; Tamma PD; Blumberg EA; Alby K; Bilker WB; Werzen A; Ammazzalorso A; Tolomeo P; Omorogbe J; Pineles L; Han JH
    Transplantation; 2023 Jan; 107(1):254-263. PubMed ID: 35856636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial stewardship programme associated with earlier prescription of in vitro susceptible therapy and lower 14-day mortality in patients with carbapenem-resistant Enterobacterales bacteraemia: a cohort study.
    Barros A; Monroy H; Bergo P; Beck E; David L; Rigatto MH
    J Glob Antimicrob Resist; 2022 Mar; 28():130-135. PubMed ID: 34933141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score-matched analysis.
    Chen Z; Xu Z; Wu H; Chen L; Gao S; Chen Y
    Am J Infect Control; 2019 Jun; 47(6):677-682. PubMed ID: 30554879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of and risk factors for carbapenem-resistant
    Barber KE; Wagner JL; Larry RC; Stover KR
    J Med Microbiol; 2021 Feb; 70(2):. PubMed ID: 33263511
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
    Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
    Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
    Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of active surveillance of carbapenem-resistant Enterobacterales (CRE) in colonization rates in critically ill patients.
    Gomides MDA; Fontes AMS; Silveira AOSM; Matoso DC; Ferreira AL; Sadoyama G
    PLoS One; 2022; 17(1):e0262554. PubMed ID: 35051212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.
    Alraddadi BM; Heaphy ELG; Aljishi Y; Ahmed W; Eljaaly K; Al-Turkistani HH; Alshukairi AN; Qutub MO; Alodini K; Alosaimi R; Hassan W; Attalah D; Alswaiel R; Saeedi MF; Al-Hamzi MA; Hefni LK; Almaghrabi RS; Anani M; Althaqafi A
    BMC Infect Dis; 2022 Jun; 22(1):542. PubMed ID: 35698046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of antibiotic therapy for carbapenem-resistant Enterobacterales (CRE) bloodstream infections in hospitalized US veterans.
    Wilson GM; Fitzpatrick MA; Suda KJ; Smith BM; Gonzalez B; Jones M; Schweizer ML; Evans M; Evans CT
    JAC Antimicrob Resist; 2022 Oct; 4(5):dlac106. PubMed ID: 36320448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.
    Lee GC; Lawson KA; Burgess DS
    Ann Pharmacother; 2013 Sep; 47(9):1115-21. PubMed ID: 24259725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 - 2020: An update.
    Lowe M; Shuping L; Perovic O
    S Afr Med J; 2022 Aug; 112(8):542-552. PubMed ID: 36214398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital.
    Meng X; Liu S; Duan J; Huang X; Zhou P; Xiong X; Gong R; Zhang Y; Liu Y; Fu C; Li C; Wu A
    BMC Infect Dis; 2017 Jan; 17(1):82. PubMed ID: 28095785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics, risk factors, and outcomes of patients hospitalized in the US military health system with carbapenem-resistant Enterobacteriaceae infection.
    Adams DJ; Susi A; Nylund CM
    Am J Infect Control; 2020 Jun; 48(6):644-649. PubMed ID: 31757476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study.
    Ahn JY; Song JE; Kim MH; Choi H; Kim JK; Ann HW; Kim JH; Jeon Y; Jeong SJ; Kim SB; Ku NS; Han SH; Song YG; Yong D; Lee K; Kim JM; Choi JY
    Am J Infect Control; 2014 Jun; 42(6):621-5. PubMed ID: 24837112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.